Evolent Health

Evolent Health, Inc. engages in the provision of health care delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolent Health excels in Q4 2022, eyes growth with Humana

Evolent Health posts strong financials, exceeding revenue and EBITDA targets.
Strategic partnerships and focus on organic growth drive value creation.
Challenges lie in maintaining growth momentum and effective execution.
Opportunities include margin expansion, capital optimization, and Humana partnerships.

Evolent Health surpasses Q1 expectations, eyes revenue growth opportunities

Evolent Health's Q1 performance exceeded expectations, driven by strong revenue growth and margin expansion initiatives. While facing challenges like revenue adjustments and Medicaid rebates, the company remains focused on capitalizing on growth opportunities through strategic partnerships and operational efficiencies.

Evolent Health excels in Q2, eyes $300M EBITDA target

Evolent Health's robust performance in Q2, strategic partnerships, and focus on organic growth position it well to achieve its financial targets.
Challenges lie in Medicaid membership declines, capital allocation optimization, and refinancing decisions amidst market uncertainties.
Opportunities in patient-centric care, CMS changes, and integrated entity approach offer avenues for growth and differentiation in the market.

Evolent Health surpasses Q3 expectations, eyes growth in specialty care

Evolent Health's Q3 performance exceeded expectations, driven by strong revenue growth and profitability, underpinned by strategic partnerships and a unique care model.
Despite challenges in ramping up Performance Suite adoption and maintaining cost control, the company's focus on growth and value creation positions it well for future success.
Opportunities in expanding specialty offerings and leveraging new partnerships highlight Evolent's growth potential and commitment to delivering value in the healthcare sector.

Evolent Health exceeds 2023 targets, eyes growth through partnerships

Evolent Health delivered strong financial results in Q4 2023, surpassing its 2023 targets and setting ambitious goals for 2024, driven by Specialty Care offerings and new revenue agreements.
While facing challenges related to medical utilization and new product launches, the company remains focused on organic growth and profitability, supported by a strategic approach to expansion.
Opportunities in cross-selling, new state expansions, and imaging capabilities position Evolent Health for continued growth and revenue diversification in the healthcare sector.

Evolent Health reports robust Q1 earnings, eyes margin improvements

Evolent Health's Q1 performance showcased strong revenue growth and EBITDA in line with guidance.
The company is optimistic about margin improvements, revenue expansion, and maintaining a balanced pipeline.
Challenges include margin impact from new go-lives and ongoing payer negotiations amid cost pressures.
Opportunities lie in improving gross margins, leveraging population changes, and focusing on cash flow expectations.

Evolent Health reports robust Q2 earnings, eyes growth opportunities ahead

Evolent Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives, and a positive outlook for future growth. The company's focus on revenue diversification, margin optimization, and disciplined financial management positions it well for continued success in the evolving healthcare landscape.

Evolent Health revises outlook after Q3 challenges, secures financing

Evolent Health navigated higher medical costs impacting Q3 results, leading to a revised outlook for 2024. Despite challenges in managing expenses and oncology costs, the company remains committed to growth and securing new revenue agreements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

NEW YORK, Oct. 6, 2021 /PRNewswire/ -- WindRose Health Investors, LLC ("WindRose"), the New York-based healthcare private equity firm, announced today that it has completed the sale of Vital Decisions, LLC ("Vital Decisions" or the "Company") to Evolent Health, Inc. ("Evolent Health"). Vital Decisions will report into Evolent's specialty management offering, New Century Health, and will be consolidated into Evolent's Clinical Solutions segment.

WindRose Health Investors Completes the Sale of Vital Decisions to Evolent Health

Evolent Health Inc. is a small innovative healthcare services outfit bridging the gap between provider and payer. Sweeping shifts in the healthcare industry are attracting widespread technological innovation.

Options Insights: Feeding Frenzy In Evolent Health Inc. Call Options

There's a rumor going around that Walgreens Boots Alliance wants to acquire the struggling administrative assistant business.

Here's Why Evolent Health Is Up 18.8% This Week

Swirling buyout rumors continue to bring the bulls to the healthcare stock.

Why Evolent Health Blasted 7% Higher on Thursday

Walgreens

Walgreens Boots Alliance Inc (NASDAQ: WBA) is reportedly mulling an acquisition of Evolent Health Inc (NYSE: EVH). Citing people familiar with the matter, Bloomberg reported that the talks are ongoing, and there is no certainty Walgreens will move forward with an offer to buy the company.

Walgreens In Talks To Buy Evolent Health: Bloomberg

Pharmacy chain Walgreens Boots Alliance is considering an acquisition of healthcare IT firm Evolent Health Inc, Bloomberg reported on Wednesday, citing people familiar with the matter.

Walgreens weighing deal to buy Evolent Health - Bloomberg

Evolent Health's stock jumped as much as 18% in afternoon trading Wednesday after Bloomberg reported that Walgreens was considering buying the company.

Evolent Health stock jumps after report of possible Walgreens takeover

WASHINGTON, Aug. 30, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, announced today that its Evolent Care Partners (ECP) business unit saved Medicare more than $21 million in 2020, its inaugural year as the owner of an accountable care organization (ACO). ECP and the independent physician participants in its ACO network will receive $15.8 million in shared savings for exceeding quality and cost targets in 2020, according to recently released performance data from the Medicare Shared Savings Program (MSSP).

Evolent Health Exceeds Quality Standards and Saves Medicare $21 Million through its Medicare Shared Savings Program ACO

Evolent Health, Inc. (EVH) CEO Seth Blackley on Q2 2021 Results - Earnings Call Transcript

Evolent Health (EVH) delivered earnings and revenue surprises of 66.67% and 2.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Reports Q2 Loss, Tops Revenue Estimates

WASHINGTON, Aug. 4, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) – Evolent Health, Inc. ("Evolent"), and WindRose Health Investors ("WindRose") announced today that they have entered into a definitive agreement for Evolent to acquire WindRose's portfolio company Vital Decisions for $85 million, with an additional earn out of up to $45 million. Vital Decisions will report into Evolent's specialty management offering, New Century Health, and will be consolidated into Evolent's Clinical Solutions segment.

Evolent Health Announces Agreement to Acquire Vital Decisions, Expanding its Depth and Breadth in Specialty Care Management

WASHINGTON, Aug. 4, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended June 30, 2021. Highlights from the second quarter of 2021 announcement include: Quarter ended June 30, 2021: GAAP revenue of $222.1 million, an increase of $4.8 million, or 2.2%, from the three months ended June 30, 2020.

Evolent Health Announces Second Quarter 2021 Results

Evolent Health (EVH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolent Health (EVH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

WASHINGTON, July 21, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its second quarter 2021 operating results on Wednesday, August 4, 2021 after market close, with a conference call to follow at 6:00 p.m. Eastern Time.

Evolent Health, Inc. to Release Second Quarter 2021 Operating Results and Host Conference Call on Wednesday, August 4, 2021

Does Evolent Health (EVH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Evolent Health (EVH) is a Great Choice

WASHINGTON, June 22, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, has been named to the Parity.org Best Companies for Women to Advance List 2021. This list recognizes organizations that have implemented a mix of exemplary benefits, policies and programs that ensure women have significant opportunities to advance their careers.

Evolent Health Named to Parity.org's Best Companies for Women to Advance List 2021

Evolent Health, Inc. (EVH) CEO Seth Blackley on Q1 2021 Results - Earnings Call Transcript

Why Evolent Health Shares Fell on Thursday

Evolent Health (EVH) delivered earnings and revenue surprises of 87.50% and 2.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Reports Q1 Loss, Tops Revenue Estimates

WASHINGTON, May 5, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended March 31, 2021. Highlights from the first quarter of 2021 announcement include: Quarter ended March 31, 2021: GAAP revenue of $215.1 million.

Evolent Health Announces First Quarter 2021 Results

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Evolent Health (EVH) Report Negative Earnings Next Week? What You Should Know

WASHINGTON, April 20, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its first quarter 2021 operating results on Wednesday, May 5, 2021 after market close, with a conference call to follow at 6:00 p.m. Eastern Time.

Evolent Health, Inc. to Release First Quarter 2021 Operating Results and Host Conference Call on Wednesday, May 5, 2021

ATLANTA--(BUSINESS WIRE)--Implantable Provider Group, Inc. (“IPG” or the “Company”), a leading provider of surgical cost management solutions, today announced a significant investment from TPG Growth, the middle-market and growth equity platform of alternative asset firm TPG. TPG Growth will partner with IPG's existing management team to invest behind its core value proposition, further support existing customer relationships, and expand into new geographies. Partnering with health plans, devic

IPG Receives Significant Investment From TPG

CHICAGO--(BUSINESS WIRE)--On April 1, 10:30 a.m., Chicago Black clergy launch a Covid-19 vaccine education program to reach up to 1M Black and Latinx congregants over Easter.

500 Chicago Area Black Churches to Launch Covid-19 Vaccine Video Campaign During Easter Weekend Services

SAN DIEGO, March 28, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company") against certain of its officers and directors. Specifically, a class-action lawsuit pending in the Eastern District of Virginia against Evolvent and certain of its current and former officers recently survived, in part, certain defendants' attempts to have the case dismissed.

Evolvent (EVH) Alert: Johnson Fistel Announces Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?

News for Evolent Health Stock (EVH)